• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Medpace Holdings Inc.

    6/4/26 4:06:40 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    8-K
    false 0001668397 0001668397 2026-06-01 2026-06-01
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 1, 2026

     

     

    MEDPACE HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-37856   32-0434904

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    5375 Medpace Way

    Cincinnati, Ohio 45227

    (Address of Principal Executive Offices, and Zip Code)

    (513) 579-9911

    Registrant’s Telephone Number, Including Area Code

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock $0.01 par value   MEDP   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Effective June 1, 2026, Medpace Holdings, Inc. (the “Company”) appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations.

    Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.

    Mr. Hansman has no family relationships with any current director, director nominee, or executive officer of the Company, and there are no transactions or proposed transactions, to which the Company is a party, or intended to be a party, in which he has, or will have, a material interest subject to disclosure under Item 404(a) of Regulation S-K. Mr. Hansman was not appointed as the Company’s Executive Vice President, Operations, pursuant to any arrangement or understanding with any other person.

    In connection with his appointment, Mr. Hansman will receive an annual base salary of $492,250 and will be eligible to participate in the short-term incentive compensation plan providing target cash bonus opportunities (expressed as a percentage of base salary and as described in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 1, 2026) and the Company’s long-term equity incentive plan at the discretion of the Compensation Committee of the Board of Directors of the Company.

    Mr. Hansman and the Company have entered into the Company’s standard indemnification agreement for directors and executive officers.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        MEDPACE HOLDINGS, INC.
    Date: June 4, 2026     By:  

    /s/ Stephen P. Ewald

        Name:   Stephen P. Ewald
        Title:   General Counsel and Corporate Secretary
    Get the next $MEDP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    3/6/2026$500.00Underweight → Equal Weight
    Barclays
    3/3/2026$522.00Outperform
    RBC Capital Mkts
    2/18/2026$419.00Sell → Hold
    TD Cowen
    2/13/2026$560.00Hold → Buy
    Jefferies
    2/10/2026$564.00Neutral → Outperform
    Robert W. Baird
    11/13/2025$600.00Market Perform
    BMO Capital Markets
    10/2/2025$425.00Equal Weight → Underweight
    Barclays
    9/3/2025$474.00Buy → Neutral
    Rothschild & Co Redburn
    More analyst ratings

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medpace Holdings, Inc. Reports First Quarter 2026 Results

    Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of

    4/22/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

    3/24/26 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

    2/9/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    2/28/25 4:39:05 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medpace upgraded by Barclays with a new price target

    Barclays upgraded Medpace from Underweight to Equal Weight and set a new price target of $500.00

    3/6/26 8:19:59 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    RBC Capital Mkts initiated coverage on Medpace with a new price target

    RBC Capital Mkts initiated coverage of Medpace with a rating of Outperform and set a new price target of $522.00

    3/3/26 8:27:50 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace upgraded by TD Cowen with a new price target

    TD Cowen upgraded Medpace from Sell to Hold and set a new price target of $419.00

    2/18/26 7:50:53 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    SEC Filings

    View All

    SEC Form 8-K filed by Medpace Holdings Inc.

    8-K - Medpace Holdings, Inc. (0001668397) (Filer)

    6/4/26 4:06:40 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by Medpace Holdings Inc.

    8-K - Medpace Holdings, Inc. (0001668397) (Filer)

    5/19/26 2:43:27 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Medpace Holdings Inc.

    10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

    4/23/26 4:03:37 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)

    3 - Medpace Holdings, Inc. (0001668397) (Issuer)

    6/4/26 4:44:09 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    6/1/26 4:27:45 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Zander Dani S.

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    5/18/26 5:30:14 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    View All

    Medpace Holdings, Inc. Announces Senior Leadership Changes

    Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

    7/26/21 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Financials

    Live finance-specific insights

    View All

    Medpace Holdings, Inc. Reports First Quarter 2026 Results

    Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of

    4/22/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

    3/24/26 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

    2/9/26 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    3/8/24 4:28:58 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/28/24 5:04:01 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

    SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/13/24 5:09:38 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care